anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression and has been utilized to treat persons suffering from chronic pain. The approved method for treatment is 10Hz stimulation for 40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been very successful in real world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session). Recently, researchers have aggressively pursued modifying the treatment parameters to reduce treatment times with some preliminary success. This study intends to further modify the parameters to create a more rapid form of the treatment and look at the change in neuroimaging biomarkers.
PURPOSE OF REVIEW: The vaginal microbiome has a fundamental role in supporting optimal vaginal, reproductive, and sexual health. Conversely, dysbiosis of the vaginal microbiome is linked to vaginal symptoms and adverse health outcomes. This review summarizes recent literature concerning the role of the vaginal microbiome in health and disease, with a focus on the most common vaginal dysbiosis, bacterial vaginosis.
RECENT FINDINGS: Molecular studies have expanded our understanding of the composition of the vaginal microbiome. Lactic acid-producing lactobacilli are an important component of host defences against pathogens, whereas a paucity of lactobacilli is associated with adverse sequelae. Bacterial vaginosis is characterized by low levels of lactobacilli and increased levels of nonoptimal anaerobes; however, the exact cause remains unclear. Furthermore, despite decades of research, bacterial vaginosis recurrence rates following standard treatment are unacceptably high. Strategies to improve bacterial vaginosis cure and promote an optimal lactobacilli-dominated vaginal microbiome are being investigated. Importantly, historical and emerging evidence supports the sexual transmission of bacterial vaginosis, which opens exciting opportunities for novel treatments that incorporate partners.
SUMMARY: A mechanistic and deeper understanding of the vaginal microbiome in health and disease is needed to inform ongoing development of therapeutics to improve bacterial vaginosis cure. Partner treatment holds promise for improving bacterial vaginosis cure.
Juvenile neurolupus presents primarily with neuropsychiatric manifestations which may also be the initial presentation. Such primary neuropsychiatric SLE (NPSLE) events are a consequence either of microvasculopathy and thrombosis, or of autoantibodies and inflammatory mediators. Diagnosis of NPSLE requires the exclusion of other causes, and clinical assessment directs the selection of appropriate investigations. These investigations include measurement of autoantibodies, analysis of cerebrospinal fluid, electrophysiological studies, neuropsychological assessment and neuroimaging to evaluate brain structure and function. In our patient, the disease presented with chronic headache initially diagnosed as migraine, followed by fever and paraparesis. Fundoscopy showed retinal haemorrhages. Investigations revealed anaemia, neutrophilic leucocytosis, thrombocytopenia and raised inflammatory markers (ESR 119 mm/h CRP 58 mg/L) and high globulin. MRI brain showed diffuse meningeal enhancement resembling meningitis but CSF analysis was normal. ANA and dsDNA were positive with low C3, C4. All diffuse meningeal enhancements may not be meningitis and one needs to corroborate all the clinical, biochemical and imaging analyses to come to a diagnosis.
Participants receive single dose of NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing protein structures, facilitating the repair or degradation of damaged proteins, and maintaining proteostasis and cellular functions. Extensive research has demonstrated that heat shock proteins are highly expressed in cancers and closely associated with tumorigenesis and progression. The "Hallmarks of Cancer" are the core features of cancer biology that collectively define a series of functional characteristics acquired by cells as they transition from a normal state to a state of tumor growth, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabled replicative immortality, the induction of angiogenesis, and the activation of invasion and metastasis. The pivotal roles of heat shock proteins in modulating the hallmarks of cancer through the activation or inhibition of various signaling pathways has been well documented. Therefore, this review provides an overview of the roles of heat shock proteins in vital biological processes from the perspective of the hallmarks of cancer and summarizes the small-molecule inhibitors that target heat shock proteins to regulate various cancer hallmarks. Moreover, we further discuss combination therapy strategies involving heat shock proteins and promising dual-target inhibitors to highlight the potential of targeting heat shock proteins for cancer treatment. In summary, this review highlights how targeting heat shock proteins could regulate the hallmarks of cancer, which will provide valuable information to better elucidate and understand the roles of heat shock proteins in oncology and the mechanisms of cancer occurrence and development and aid in the development of more efficacious and less toxic novel anticancer agents.
The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
PURPOSE: A hydrogel patch is provided to enable a consumer to confirm the heat absorption state or replacement time of the patch. CONSTITUTION: A hydrogel patch comprises a hydrogel layer(10), adhesion cloth(20), and a display unit(30). The hydrogel layer is equipped with gel which is manufactured by the dispersion medium of water or a component including water. The hydrogel patch is formed by using acryl polymer or natural polymer. The adhesion cloth is formed on the hydrogel layer. The display unit is printed on the adhesion cloth. The display unit is equipped with a color change unit. The color change unit is equipped with a first color change interval, a second first color change interval, and a third color change interval.
Physical exercise is suggested to promote hippocampal neuroplasticity by increasing circulating neurotrophic and anti-inflammatory factors. Our aim was to explore the interplay between the effect of progressive resistance exercise on blood biomarker levels, hippocampal neurometabolite levels and hippocampal volume in older adults with a low compared to a high risk of mild cognitive impairment (MCI). Seventy apparently healthy male/female older adults (aged 60-85 years old) were randomly allocated to a 12 week lower limb progressive resistance or no intervention, stratified for low (< 26/30) or high (≥ 26/30) Montreal Cognitive Assessment (MoCA) score, indicating MCI risk. Outcome measures were blood levels of insulin-like growth factor-1 (IGF-1), interleukin-6 (IL-6) or kynurenine (KYN); hippocampal total and subfield volumes of the cornu ammonis 1 (CA1) and 4 (CA4), subiculum, presubiculum, and dentate gyrus measured with magnetic resonance imaging (MRI); and hippocampus neurometabolites including total N-acetylaspartate (NAA), myo-inositol (mIns), and total creatine (Cr) measured with proton magnetic resonance spectroscopy (1H-MRS). We evaluated the intervention effect, cognitive status effect, their interaction and the bivariate relationship between exercise-induced changes between the outcome measures. Higher kynurenine levels (p = 0.015) and lower subiculum volumes (p = 0.043) were found in older adults with high MCI risk compared to older adults with low MCI risk. Exercise-induced CA1 volume changes were negatively correlated with hippocampal tNAA/mIns level changes (r = -0.605, p = 0.006). This study provides valuable insight in the multifactorial processes related to resistance training in older adults with low or high MCI risk.
PURPOSE: This research aimed to evaluate the expression level of Homeobox A9 (HOXA9) and its role in tumorigenesis of hepatocellular carcinoma (HCC).
METHODS: Bioinformatic analysis, qPCR and Western blot analysis of clinical samples were employed to evaluate mRNA and protein levels of HOXA9 in HCC patients and cell lines. In vitro cell proliferation, migration and invasion, cloning formation, xenograft tumor model, wound healing and apoptosis assays, RNA sequencing analysis of RPL38-silenced HCC-LM3 cells and qPCR, Western blot analysis were performed for validation. Analysis of HOXA9-related genes were conducted to identify their relationships between HOXA9.
RESULTS: HOXA9 is dramatically upregulated in HCC. Upregulation of HOXA9 in HCC predicts poor survival of patients. Besides, HOXA9 promotes proliferation, metastasis and prevents apoptosis in HCC in vitro. In addition, HOXA9 controlled by Ribosomal protein RPL38 is upregulated in HCC. Bioinformatic analysis also indicated that HOXA9 is involved in the regulation of DNA methylation and immune infiltration in HCC.
CONCLUSION: HOXA9 is dramatically upregulated in hepatocellular carcinoma and predicts poor prognosis. Besides, HOXA9 promoted proliferation and metastasis and prevented apoptosis in vitro, which is regulated by Ribosomal protein RPL38 in HCC.
The personal care composition for shaving is a pre-shaving conditioner for the skin and hair. The composition is water-based and includes aloe vera gel, vitamins A and E, an esterquat, preferably dipalmitoylethyldimonium chloride, and a thickener. A fragrance may be added to the composition if desired. The composition is applied to the area of skin that is to be shaven while in the shower. The composition should remain on the skin for at least two minutes and is then washed off. Once the composition is wiped off the skin, the user may shave in their traditional manner using a shaving cream or gel.
In the overall study population of 60 subjects who applied to the Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital Chest Diseases Clinic. The study population was selected regardless of age and gender. Participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution CT scan within the previous year. The study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 European Respiratory Society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. The study enrolled healthy controls (n=30) through advertisements who had acceptable chest X-ray and spirometry results and no lower airway symptoms or serious systemic disorders. The study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. SIRT-1 and MMP-9 levels in the serum of the study group were determined by the ELISA method.
A 30-week, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of BYETTA (n = 137) versus placebo (n = 122) when added to titrated insulin glargine, with or without metformin and/or thiazolidinedione, in patients with type 2 diabetes with inadequate glycemic control.

All patients assigned to BYETTA initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients assigned to BYETTA had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the trial. BYETTA or placebo was injected subcutaneously before the morning and evening meals. Patients with an HbA1c ≤8.0% decreased their prestudy dose of insulin glargine by 20% and patients with an HbA1c ≥8.1% maintained their current dose of insulin glargine. Five weeks after initiating randomized treatment, insulin doses were titrated with guidance from the investigator toward predefined fasting glucose targets according to the dose titration algorithm provided in Table 9. The majority of patients (78%) were Caucasian, 10% were American Indian or Alaska Native, 9% were Black, 3% were Asian, and 0.8% were of multiple origins.

The primary endpoint was the change in HbA1c from baseline to Week 30. Compared to placebo, BYETTA 10 mcg BID resulted in statistically significant reductions in HbA1c from baseline at Week 30 (Table 8) in patients receiving titrated insulin glargine.
Investigators will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
OBJECTIVES: Sepsis is a life-threatening infectious disease in which an immune inflammatory response is triggered. The potential effect of ferroptosis-related genes (FRGs) in inflammation of sepsis remained unclear. We focused on identifying and validating core FRGs and their association with immune infiltration in blood from currently all patients with sepsis.
METHODS: All current raw data of septic blood were obtained from Gene Expression Omnibus. After removing the batch effect merging into a complete dataset and obtaining Diferentially expressed genes (DEGs). Common cross-talk genes were identified from DEGs and FRGs. WGCNA, GO, KEGG, PPI, GESA, ROC curves, and LASSO regression analysis were performed to indentify and validate key genes based on external septic datasets. Infiltrated immune cells in 2 hub genes (MAPK14 and ACSL4) were conducted using CIBERSORT algorithm and Spearman correlation analysis. Further, the expressions of 2 core FRGs were verified in the LPS-induced ALI and cardiac injury sepsis mice.
RESULTS: MAPK14 and ACSL4 were identified, mostly enriched in T cell infiltration through NOD-like receptor signaling pathway according to the high or low 2 hub genes expression. The upregulated 2 ferroptosis-related genes were validated in LPS-induced ALI and cardiac injury mice, accompanied by upregulation of the NLRP3 pathway.
CONCLUSION: MAPK14 and ACSL4 could become robustly reliable and promising biomarkers for sepsis by regulating ferroptosis through the NLRP3 pathway, which is mainly associated with T-cell infiltration.
MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10\^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromyci n A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may b e one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.</ SDOAB>
Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely microbiology, clinical and laboratory diagnosis and immunology. A method for preparing hyperimmune rickettsial serums is as follows. Male 10-12-month Chinchilla rabbits 2.5-3.0 kg are immunised at two stages. At the primary immunisation, a mixture of 10% suspension of the rickettsial infectious material (0.5 ml) and Freund's complete adjuvant taken in volume 1.5 times exceeding the amount of the infectious material (0.75 ml) is administered. To stimulate the primary immune response, the mixture injected once in intradermal paravertebral microdoses in 40 points. The infection rickettsial material is homogenised membranes of yolk sacs of chicken embryos infected with R. prowazekii, or homogenised spleen of inbred albino mice 16-18 g infected with rickettsial C.burnetii or R. sibirica. Thereafter 45 day later, provided reducing the antibody titres produced as a result of the primary immunisation, up to 1:20-1:80, the re-immunisation is started: four-fold intravenous injections of the inactivated antigens of the relevant rickettsial pathogens to complement fixation in the concentration of at least 4 antigen units in 1 ml with increasing doses of 1.0, 1.5, 2.0 and 2.5 ml, every 3 days after each injection. For the purpose of the cytokine imbalance correction and additional stimulation of antibody formation at the stage of re-immunisation, recombinant human IL-2 (roncoleukin) in a volume of 1.0 ml at a dose of 250 000 ME is additionally subcutaneously administered. Total blood sampling for preparing serums is performed on the 14day following the last intravenous injection and specific antibody titres of in indirect immunofluorescent technique not less than 1:5120-1:10240. The length of a complete cycle of immunisation in accordance with the delared method is 68 days.EFFECT: invention provides reducing the length of immunisation in 2,3 times (from 158 days to 68 days) and preparing the hyperimmune sera, having the collected rickettsial antibody titres in 4-8 times, increasing the material costs for keeping producer animals in 4,7 times and reducing the labour costs in 5,2 times over a production cycle of preparing the rickettsial hyperimmune sera, saving the wages fund in 4,2 times.3 tbl, 4 ex
TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
ESBRIET is a white hard gelatin capsule; each capsule contains 267 mg of pirfenidone. The cap of the capsule is printed with “InterMune®” and “267 mg” in brown ink. The capsule is supplied either in a bottle, a 14-day titration blister pack or a 4-week maintenance blister pack.

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) (see USP Controlled Room Temperature).

Keep the bottle tightly closed. Do not use if the seal over the bottle opening is broken or missing.
<P>PROBLEM TO BE SOLVED: To provide a wild strain yeast extract useful as a cosmetics raw material.  <P>SOLUTION: The yeast extract for cosmetics material is prepared by cultivating a yeast in a medium containing glutamic acid, cysteine, and glycine with high contents and then immediately extracting with an extraction liquid containing a polyhydric alcohol without performing digestion with an enzyme in bacteria cells or with protease. The contents of glutamic acid, cysteine, and glycine are each preferably 0.1-0.5 mass% based on the total amount of the medium. The polyhydric alcohol is preferably glycerin. 1,3-Butanediol is preferably added after the extraction. The yeast is preferably one of Saccharomyces cerevisiae separated from the pericarp of grape fruits.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This study is aimed at addressing a significant void in the current literature regarding nasally administered acetaminophen pharmacokinetics. The pharmacokinetics of acetaminophen following oral and rectal administration have been well studied but to date there are no published studies determining the pharmacokinetics of acetaminophen following intranasal administration. This route is currently popular among heroin users. Understanding the pharmacokinetics of nasally administered acetaminophen will help physicians address the important clinical implications of acetaminophen toxicity in this population.

Ten healthy adult volunteers age 18 to 45 years will be recruited for this pilot project. Study participants will be randomized in permuted blocks to receive either oral or intranasal administration of a standardized 500 mg dose of acetaminophen. Blood samples will be drawn from a peripheral intravenous catheter at 0, 5, 15, 30, 45, 60, 90, 120, 150, 240, 360, and 480 minutes after study drug administration and sent to the laboratory for determination of serum acetaminophen concentration. After a one week washout period, each participant will cross over to receive 500 mg of acetaminophen via the remaining route of administration in the second arm of the study. The serial acetaminophen concentrations will be utilized to perform pharmacokinetic calculations.
PROBLEM TO BE SOLVED: To obtain a pigmentation preventing agent having excellent stability, safety, melanogenesis inhibiting action and dendrite formation inhibiting action by including a specific hydrangenol (derivative). SOLUTION: The objective preventing agent is produced by including (A) a hydrangenol (derivative) of formula (R1 and R2 are each H or a sugar residue) and as necessary (B) ascorbic acid (salt). The component A is an isocoumarin compound contained in a crude drug Amacha (Hydrangea Dulcls Follum) (a kind of herb drug). The component A can be produced by extracting the crude drug Amacha with an organic solvent, removing the solid material by filtration or centrifugal separation and purifying by chromatography. The component B is ascorbic acid (vitamin C), ascorbic acid phosphate salt, ascorbic acid sulfate salt, etc. A liquid extract, etc., of a plant containing the component B may be used as the component B.
The invention discloses preparation and processing methods of fructus rosae laevigatae capsules. According to special medicinal functions and effects of a traditional Chinese medicine fructus rosae laevigatae, a medicinal health product of fructus rosae laevigatae traditional Chinese medicine capsules is prepared by taking the traditional Chinese medicine fructus rosae laevigatae as a raw material which is scientifically matched with quantitative proportional auxiliary traditional Chinese medicinal materials through a series of processing methods. The product contains various Chinese herb medicinal materials, more effective medicinal substances and rich mineral substances required by a human body. The capsules eaten have the functions of activating spirit, increasing and filling marrow, replenishing and engendering essence, securing and activating essence, nourishing yin and tonifying Yang, strengthening bone and musculature, tonifying brain and improving eyesight, resisting diseases and prolonging life and the like. The product is scientific in formula and reasonable in match. As the product is prepared into an ultrafine powder medicine, the nutritional substances are fully and effectively refined, so that the effective nutritional substances and elements do not run off and various effective active substances are easily absorbed by the human body and quick to use. The capsules taken are remarkable in medicinal curative effect, promote body building and are very obvious in medical and medicinal health effects.